This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
MapLight Therapeutics General Counsel Kristopher Hanson reported selling 13,917 shares of Voting Common Stock in open‑market trades. The sales occurred on May 4, 2026 at weighted average prices, with individual trades ranging from $26.84 to $30.55 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted on December 29, 2025. After the sales, Hanson directly holds 176,248 shares.
MapLight Therapeutics, Inc. director and CEO Christopher A. Kroeger reported open‑market sales of Voting Common Stock. Over May 4–6, 2026, he sold a total of 49,744 shares in multiple transactions classified as open‑market sales under code S, at prices reported as weighted averages.
The filing shows these transactions were executed pursuant to a Rule 10b5‑1 trading plan adopted on December 29, 2025, meaning they were pre‑scheduled. After the reported sales, Kroeger directly holds 1,580,820 shares of Voting Common Stock and an additional 101,190 shares are held indirectly through the C&M Kroeger Nominee Trust, where he and his spouse have voting and dispositive power.
Maplight Therapeutics, Inc. notice under Form 144 reports proposed sales of Common Stock by Christopher Kroeger. The filing lists a sale of 9,135 shares on 04/15/2026 for $246,020.99 and 10,052 shares on 04/16/2026 for $275,140.33. The filing also references vested RSUs dated 07/05/2024.
Maplight Therapeutics notified a proposed sale of 36,371 shares of Common Stock, described on the form with an aggregate value of $1,116,589.70. The sale is tied to vested RSUs and listed with Jefferies LLC as the broker on 05/04/2026.
The filing also records recent dispositions by Vishwas Setia of 2,806 shares on 04/15/2026 and 116 shares on 04/16/2026.
Maplight Therapeutics reported insider sales by Erin Pennock Foff. The filing discloses a sale of 2,044 shares for $54,869.99 on 04/15/2026 and a sale of 1,169 shares for $31,997.52 on 04/16/2026. The record shows the securities originated from a vested RSU dated 07/05/2024 and lists Jefferies LLC as the broker-dealer.
Maplight Therapeutics, Inc. submitted a Form 144 notice listing 52,428 shares of common stock associated with a broker-dealer, Jefferies LLC, and showing an aggregate figure of $1,609,539.60. The filing lists prior sales by James Lillie of 1,730 and 2,783 shares on 04/15/2026 and 04/16/2026, respectively.
Maplight Therapeutics, Inc. filed a Form 144 reporting a proposed sale of 27,834 shares of Common stock. The filing lists prior sales by Kris Hanson of 1,529 shares on 04/15/2026 for $40,974.77 and 298 shares on 04/16/2026 for $8,156.77.
MapLight Therapeutics CAAO and PAO Jonathan Gillis reported open-market sales of 69,835 shares of Voting Common Stock. The transactions occurred on April 27–28, 2026, across five sales at weighted average prices such as $28.94 and $30.83 per share. All sales were executed under a Rule 10b5-1 trading plan adopted on December 26, 2025, and he continues to hold a direct equity position reported in the filing.
MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer sold 45,422 shares of Voting Common Stock in open-market transactions. The sales occurred on April 27, 2026 at weighted average prices of $28.96, $29.63, and $30.50 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, Kreitzer directly held 211,190 shares of MapLight Therapeutics common stock.
MapLight Therapeutics, Inc. reported that directors Robert Malenka, M.D., Ph.D. and Jim Trenkle, Ph.D. have decided not to stand for reelection at the company’s Annual Meeting of Stockholders scheduled for June 23, 2026. The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace them. The company stated that Dr. Malenka’s and Dr. Trenkle’s decisions were not due to any disagreement with MapLight on its operations, policies, or practices.